Is Wegovy Covered by Insurance? What to Know in 2026

Wegovy (semaglutide) costs around $1,350 per month without insurance. Whether your plan covers it depends on three things: who you’re insured through, what condition it’s being prescribed for, and whether your plan has specifically included or excluded GLP-1 weight loss drugs. The rules changed significantly in 2025 and are changing again in 2026 — and a lot of people are getting wrong answers because they’re working from outdated information.

Here’s the current state of Wegovy coverage across commercial insurance, Medicare, and Medicaid — including the July 2026 Medicare expansion that will matter to a lot of retirees.

Does Commercial Insurance Cover Wegovy?

Commercial insurance coverage for Wegovy is inconsistent and often frustrating to navigate. Nationally, only about 14% of people with commercial insurance have unrestricted coverage of Wegovy, according to GoodRx research. The vast majority of plans either exclude weight-loss drugs entirely or require prior authorization with clinical criteria that are harder to meet than people expect.

Common requirements for commercial prior authorization:

• BMI threshold: Most plans require a BMI of 30 or higher, or 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease)
• Failed prior therapies: Many plans require documented attempts at diet and exercise programs, sometimes supervised, before approving a GLP-1
• Prescribing provider: Some plans require the prescription to come from a specialist (endocrinologist, obesity medicine specialist) rather than a primary care physician
• Formulary placement: Even when covered, Wegovy is typically on Tier 4 or 5 (specialty tier) — expect 25–33% coinsurance before hitting your out-of-pocket max
• Step therapy: Some plans require trying a lower-cost alternative (like metformin or phentermine) before approving semaglutide

If your prior authorization is denied, you have the right to appeal. A letter of medical necessity from your prescribing physician with documented clinical rationale significantly improves approval odds on appeal. About 40–60% of GLP-1 prior auth denials are overturned on first appeal when supported by strong clinical documentation.

Does Medicare Cover Wegovy in 2026?

Medicare coverage for Wegovy is conditional and has specific rules that are actively changing in 2026. Here’s the current state:

Coverage for Cardiovascular Risk Reduction (Available Now)

Medicare Part D currently covers Wegovy when prescribed to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are overweight or obese. This indication was added after the FDA approved Wegovy for cardiovascular risk reduction based on the SELECT trial results. If you have documented cardiovascular disease and meet the BMI criteria, your Part D plan may cover Wegovy for this indication today — regardless of whether you also want to lose weight.

Cost structure under Part D in 2026:

• Deductible: $615 in 2026 for standard Part D plans
• Coinsurance phase: Typically 25–33% coinsurance at specialty tier pricing
• Out-of-pocket cap: $2,100 annual maximum in 2026 — once reached, your plan covers 100% for the rest of the year
• Savings card restriction: Medicare beneficiaries cannot use Novo Nordisk’s manufacturer savings card — federal law prohibits copay assistance for government insurance programs

Weight-Loss-Only Coverage: July 2026 Expansion

Medicare does not currently cover GLP-1 drugs prescribed exclusively for weight loss — federal statute has historically excluded weight-loss medications from Part D coverage. That is changing. Beginning in July 2026, Medicare is launching the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Effectiveness) pilot program, which will provide access to GLP-1 medications for weight management through select Part D plans.

Key details on the July 2026 Medicare GLP-1 bridge:

• Must have a Medicare Part D plan or Medicare Advantage plan with drug coverage
• Requires prior authorization from your healthcare provider
• Not all Part D plans will participate — coverage depends on which insurer offers your plan
• The program runs through December 2031 unless extended
• Standard Part D cost-sharing applies — you will still have out-of-pocket costs

If you’re on Medicare and want weight loss coverage through this program, check whether your current Part D plan is participating during open enrollment. Choosing the wrong plan in November 2026 could mean waiting another year.

Does Medicaid Cover Wegovy?

Medicaid coverage for Wegovy is a patchwork. Most state Medicaid programs have historically excluded weight-loss medications from their formularies. Some states cover GLP-1 drugs for obesity with documented comorbidities (type 2 diabetes, cardiovascular disease, severe hypertension). A small number of states cover for obesity alone.

The federal government issued guidance in 2024 encouraging states to expand GLP-1 coverage for Medicaid beneficiaries, but uptake has been slow due to cost concerns. If you’re on Medicaid and want Wegovy, the fastest path is asking your prescriber to document a covered comorbidity — if Wegovy is being prescribed partly to manage cardiovascular risk or blood sugar alongside weight, some states will approve it under those diagnoses even if they exclude pure weight-loss drugs.

How Much Does Wegovy Cost Without Insurance?

Wegovy’s list price is approximately $1,350 per month without insurance coverage. That’s the retail cost before any discounts or assistance programs. Actual out-of-pocket costs vary significantly based on how you access it:

• List price (no discount): ~$1,350/month
• GoodRx discounted price: ~$199/month as of 2026 — substantial reduction, but still significant over a year
• Novo Nordisk Wegovy Savings Card: Eligible commercially insured patients may pay as little as $25/month for a 28-day supply — not available to Medicare, Medicaid, TRICARE, or VA beneficiaries
• NovoCare patient assistance: Novo Nordisk’s patient assistance program provides free Wegovy to qualifying patients who are uninsured or underinsured and meet income thresholds (generally ≤400–500% of the Federal Poverty Level)

If you have commercial insurance and your plan doesn’t cover Wegovy, the savings card is usually the best path. If you’re uninsured entirely, NovoCare assistance is worth a direct application.

How to Get Wegovy Covered by Insurance: Step-by-Step

Getting approval requires preparation. Going through your insurer without documentation is the fastest way to get denied.

• Step 1 — Check your formulary first: Log into your insurance portal and search for semaglutide or Wegovy. Look for tier placement and whether prior authorization is required before your doctor submits anything
• Step 2 — Get clinical documentation in order: Your prescriber needs to document your BMI, weight-related diagnoses, and any prior weight management attempts in your chart before submitting
• Step 3 — Submit prior authorization through your prescriber: Your doctor’s office handles the PA submission — give them your insurance information and ask them to include a detailed letter of medical necessity
• Step 4 — If denied, appeal immediately: You have the right to a formal appeal. A strong appeal includes the letter of medical necessity, relevant clinical guidelines (AACE/ACE obesity treatment guidelines are useful), and any cardiovascular risk documentation if applicable
• Step 5 — Request an expedited review if medically urgent: If your prescriber documents that a delay would seriously harm your health, insurers are required to respond to expedited appeals within 72 hours

Wegovy vs. Ozempic: Does Insurance Treat Them Differently?

Yes, significantly. Ozempic (also semaglutide, same active ingredient) is FDA-approved for type 2 diabetes management — not weight loss. Medicare Part D covers Ozempic for diabetes. Most commercial plans cover Ozempic for diabetes without the same obstacles as Wegovy for weight loss.

Prescribing Ozempic off-label for weight loss when a patient doesn’t have type 2 diabetes creates insurance complications. Some plans are now specifically auditing for off-label use and denying claims. Wegovy is the on-label choice for weight management — if weight loss is the primary goal, it’s the right drug to seek coverage for rather than relying on Ozempic off-label.